Profile data is unavailable for this security.
About the company
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
- Revenue in EUR (TTM)238.28m
- Net income in EUR-189.73m
- Incorporated1998
- Employees524.00
- LocationMorphoSys AGSemmelweisstr. 7PLANEGG 82152GermanyDEU
- Phone+49 89899270
- Fax+49 8 989927222
- Websitehttps://www.morphosys.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Formycon AG | 68.64m | -42.24m | 682.44m | 224.00 | -- | 1.45 | -- | 9.94 | -2.80 | -2.80 | 4.41 | 26.65 | 0.079 | 91.54 | 2.24 | 334,839.00 | -4.86 | 3.03 | -5.17 | 3.29 | 35.52 | 31.61 | -61.53 | 10.91 | 1.00 | -- | 0.0202 | 0.00 | 16.07 | 7.86 | 370.82 | -- | 120.72 | -- |
Eckert & Ziegler SE | 246.09m | 30.01m | 702.91m | 1.08k | 23.05 | 3.11 | 16.03 | 2.86 | 1.44 | 1.26 | 11.81 | 10.67 | 0.5812 | 3.28 | 5.63 | 228,923.70 | 7.20 | 8.50 | 8.67 | 10.23 | 47.29 | 48.61 | 12.39 | 14.00 | 2.31 | 12.77 | 0.2008 | 35.09 | 10.74 | 7.84 | -2.84 | 13.22 | 33.82 | -30.12 |
Biotest AG | 684.60m | 127.00m | 1.39bn | 2.43k | 12.96 | 3.30 | -- | 2.03 | 3.21 | 3.21 | 17.30 | 12.61 | 0.5238 | 1.13 | 3.84 | 282,192.90 | 9.72 | -0.0693 | 12.10 | -0.079 | 40.94 | 28.43 | 18.55 | -0.1527 | 0.8757 | 3.86 | 0.5803 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
Dermapharm Holding SE | 1.14bn | 62.37m | 1.72bn | 3.50k | 27.50 | 3.19 | 10.39 | 1.51 | 1.16 | 1.16 | 21.09 | 10.01 | 0.6354 | 1.44 | 12.10 | 324,664.30 | 3.39 | 8.68 | 4.10 | 10.06 | 63.34 | 61.94 | 5.33 | 12.31 | 0.7852 | 2.56 | 0.6647 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
Evotec SE | 820.80m | -94.98m | 2.35bn | 5.09k | -- | 2.06 | -- | 2.87 | -0.5371 | -0.5371 | 4.64 | 6.45 | 0.3634 | 19.15 | 5.44 | 165,751.60 | -4.21 | 2.35 | -5.08 | 2.83 | 26.78 | 25.86 | -11.57 | 6.22 | 2.09 | 0.0208 | 0.3404 | 0.00 | 21.59 | 23.29 | -181.51 | -- | 59.47 | -- |
MorphoSys AG | 238.28m | -189.73m | 2.55bn | 524.00 | -- | 51.90 | -- | 10.72 | -5.58 | -5.58 | 6.94 | 1.30 | 0.1077 | 1.18 | 3.86 | 454,729.60 | -8.58 | -10.25 | -9.78 | -11.61 | 78.62 | 85.92 | -79.63 | -78.53 | 2.84 | -- | 0.8403 | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
Qiagen NV | 1.84bn | 320.35m | 8.31bn | 5.97k | 26.14 | 2.32 | 16.20 | 4.51 | 1.43 | 1.43 | 8.25 | 16.15 | 0.3169 | 1.93 | 5.38 | 309,143.70 | 5.50 | 5.41 | 6.60 | 6.53 | 62.77 | 64.65 | 17.37 | 16.35 | 1.62 | -- | 0.2839 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |